How to choose between ceritinib/ceritinib and crizotinib

In the targeted therapy of non-small cell lung cancer (NSCLC), the treatment strategy for patients with ALK-positive mutations has entered the era of precision. With the continued development of molecularly targeted drugs, Crizotinib (trade name: Xacori) and Ceritinib (Ceritinib), as important representatives of ALK inhibitors, are often used to treat advanced lung cancer in specific groups of people. But when many patients face these two drug options, they often have questions: Which of the two is better.

First of all, from the perspective of its mechanism of action, crizotinib is the first generationALK inhibitor and the first targeted drug approved for ALK-positive NSCLC. It inhibits tumor cell growth and metastasis by blocking abnormal signaling of ALK fusion protein. Crizotinib also has certain inhibitory activity on ROS1, so it is also suitable for some ROS1-positive patients. As a second-generation ALK inhibitor, ceritinib has been optimized in molecular structure and has stronger ALK inhibitory ability. Especially in patients who are resistant to crizotinib or have failed treatment, ceritinib can still exert a sustained effect. It has certain advantages in combating a variety of known drug-resistant mutations, and is especially suitable for cases that progress after crizotinib treatment.

In terms of treatment path, crizotinib is usually used as a first-line drug, especially for newly treated patients who are confirmed by genetic testing to beALK fusion positive. Because its safety and efficacy have been confirmed in multiple large-scale studies, crizotinib is still listed as the recommended first choice for patients with ALK-positive NSCLC in the treatment guidelines of many countries and regions. It is widely used clinically, and most patients can achieve better early disease control. In contrast, although ceritinib can also be used in treatment-naïve patients, it is used in more cases for "line switching" treatment after resistance to crizotinib. Its strong penetration and control of central nervous system lesions give it certain advantages in the treatment of lung cancer brain metastases, an area that crizotinib is difficult to completely replace.

In addition, there are differences in the spectrum of side effects between the two. Common adverse reactions of crizotinib focus on visual abnormalities, gastrointestinal reactions and mild liver function fluctuations. The overall tolerability of crizotinib is good and it is suitable for use by a wide range of people. While ceritinib is more powerful in inhibiting tumors, it is also associated with a higher proportion of risks such as gastrointestinal discomfort, abnormal liver function, and elevated blood sugar. Some patients may need more frequent dose adjustments in the early stages of medication. Because of this, the use of ceritinib relies more on the close management of professional doctors, especially in the elderly or patients with underlying diseases, and more attention needs to be paid to their individual tolerance.

In clinical practice, doctors usually select drugs based on a comprehensive evaluation of multiple factors, including gene mutation subtypes, previous treatment history, whether there are brain metastases, the patient's physical condition, drug availability, and financial affordability. If ALK-positive patients are diagnosed for the first time, have no brain metastasis, are in good condition, hope to have a moderate financial burden, and have unclear resistance mechanisms, crizotinib can be the first choice. If the patient has progressed on crizotinib treatment, or genetic analysis suggests the presence of crizotinib-resistant mutations, especially T790M mutations, or is associated with a higher risk of brain metastasis, it will be more scientific and reasonable to choose ceritinib.

Reference materials:https://go.drugbank.com/drugs/DB09063